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 Highlights  
 Al at human dietary levels reaches a threshold to induce cardiovascular dysfunction.  
 Al exposure at low doses promotes vascular dysfunction and increases blood pressure.  
 Al induces endothelial dysfunction and impairs endothelial NO bioavailability.  
 This study raises the concern regarding safe values for human exposure to Al.  
 
 
Abstract 
 Aluminum (Al) is a non-essential metal and a significant environmental contaminant and is 
associated with a number of human diseases including cardiovascular disease. We investigated the effects 
of Al exposure at doses similar to human dietary levels on the cardiovascular system over a 60 day period. 
Wistar male rats were divided into two major groups and received orally: 1) Low aluminum level - rats 
were subdivided and treated for 60 days as follows: a) Untreated - ultrapure water; b) AlCl3 at a dose of 8.3 
mg/kg bw for 60 days, representing human Al exposure by diet; and 2) High aluminum level - rats were 
subdivided and treated for 42 days as follows: C) Untreated – ultrapure water; d) AlCl3 at 100 mg/kg bw 
for 42 days, representing a high level of human exposure to Al. Effects on systolic blood pressure (SBP) 
and vascular function of aortic and mesenteric resistance arteries (MRA) were studied. Endothelium and 
smooth muscle integrity were evaluated by concentration-response curves to acetylcholine (ACh) and 
sodium nitroprusside. Vasoconstrictor responses to phenylephrine (Phe) in the presence and absence of 
endothelium and in the presence of the NOS inhibitor L-NAME, the potassium channels blocker TEA, the 
NAD(P)H oxidase inhibitor apocynin, superoxide dismutase (SOD), the non-selective COX inhibitor 
indomethacin and the selective COX-2 inhibitor NS 398 were analyzed. Vascular reactive oxygen species 
(ROS), lipid peroxidation and total antioxidant capacity, were measured. The mRNA expressions of eNOS, 
NAD(P)H oxidase 1 and 2, SOD1, COX-2 and thromboxane A2 receptor (TXA-2 R) were also investigated. 
Al exposure at human dietary levels impaired the cardiovascular system and these effects were almost the 
same as Al exposure at much higher levels. Al increased SBP, decreased ACh-induced relaxation, increased 
response to Phe, decreased endothelial modulation of vasoconstrictor responses, the bioavailability of nitric 
oxide (NO), the involvement of potassium channels on vascular responses, as well as increased ROS 
production from NAD(P)H oxidase and contractile prostanoids mainly from COX-2 in both aorta and 
mesenteric arteries. Al exposure increased vascular ROS production and lipid peroxidation as well as 
altered the antioxidant status in aorta and MRA. Al decreased vascular eNOS and SOD1 mRNA levels and 
increased the NAD(P)H oxidase 1, COX-2 and TXA-2 R mRNA levels. Our results point to an excess of 
ROS mainly from NAD(P)H oxidase after Al exposure and the increased vascular prostanoids from COX-
2 acting in concert to decrease NO bioavailability, thus inducing vascular dysfunction and increasing blood 
pressure. Therefore, 60-day chronic exposure to Al, which reflects common human dietary Al intake, 
appears to pose a risk for the cardiovascular system.  
Keywords: metal; cardiovascular risk; vascular impairment; oxidative stress. 
1. Introduction 
 Aluminum (Al) is the most common metal in the Earth’s crust and its versatile properties as several 
Al compounds bring us in direct contact with this non-essential metal (Exley 2012). Human exposure to Al 
through myriad ways is inevitable (Exley 2013). In 2007, the Joint Food and Agriculture 
Organization/World Health Organization Expert Committee on Food Additives (JECFA) followed in 2008 
by the European Food Safety Authority (EFSA), have adjusted the Provisional Tolerable Weekly Intake 
(PTWI) of Al for humans to 1 mg Al/Kg body weight (b.w.) (EFSA 2008; WHO 2007). However, it is 
known that the PTWI of Al may be exceeded by humans (Fekete et al. 2013; Gonzalez-Weller et al. 2010; 
Yang et al. 2014). Despite its ubiquity Al has no known biological function, it is not beneficial and it is 
only toxic (Exley 2009). Therefore, the burgeoning increase in human exposure to Al has been concomitant 
with an increased development of Al-related adverse effects (Exley 2012; Klein et al. 2014). The 
accumulation of Al compounds in the human body has been associated with several conditions such as 
neurological disorders (Crépeaux et al. 2017; Mirza et al.  2016), macrophagic myofascitis (Gherardi et al. 
2016), microcytic anemia (Barata et al. 1996) and osteopenia (Li et al. 2011). 
 Previous studies have payed attention to the relationship between Al exposure and cardiovascular 
risk (Korchazhkina et al. 1999; Lind et al 2012; Subrahmanyam et al. 2016). In the last years, several cohort 
studies have supported a possible role for Al in cardiovascular disease (Costello et al. 2014; Neophytou et 
al. 2016; Subrahmanyam et al. 2016). For example, research has shown that exposure to airborne particles 
of Al with an aerodynamic diameter <2.5 μm are a strong predictor of ischemic heart disease risk in Al 
industry workers (Costello et al. 2014; Neophytou et al. 2016). Al appears to have high affinity to human 
endothelial cells showing an ability to be accumulated in several human arteries (Bhattacharjee et al. 2013; 
Minami et al. 2001). Moreover, the circulating presence of Al seems to be a contributor for arterial stiffness 
in healthy individuals (Subrahmanyam et al. 2016) and to atherosclerosis plaques formation in the elderly 
(Lind et al. 2012).   
 These epidemiological studies are supported by a number of experimental studies. Animals 
exposed to up to 256 mg Al/kg bw over 120 days showed an increase of blood pressure and impairments 
in erythrocyte membranes (Zhang et al. 2015). Moreover, a single intraperitoneal injection of Al at 0.5 
mg/kg promoted up-regulation of renin expression in rats (Ezomo et al. 2009). At the vascular bed, our 
group has recently reported that an acute exposure to Al was sufficient to promote vascular dysfunction 
with a reduction of vascular reactivity (Schmidt et al. 2016). Data thus far in this area have been obtained 
in studies where the exposure to Al might be considered as unrealistically high. Therefore we have looked 
to address this discrepancy by studying cardiovascular function in rats exposed to both a high level of Al 
and also one that better mimics human exposure to Al in the diet. 
2. Materials and methods 
2.1 Animals 
Three-month-old male Wistar rats (360 ± 11.2 g) were obtained from the Central Animal Laboratory 
of the Federal University of Santa Maria, Rio Grande do Sul, Brazil. During treatment, rats were housed at 
a constant room temperature, humidity, and light cycle (12:12h light-dark), giving free access to water and 
fed with a standard chow ad libitum. All experiments were conducted in compliance with the guidelines 
for biomedical research stated by the Brazilian Societies of Experimental Biology and approved by the 
Ethics Committee on Animal Use Experimentation of the Federal University of Pampa, Uruguaiana, Rio 
Grande do Sul, Brazil (Process Number: 028/2014). 
Rats were divided into two major groups, according to Martinez et al. (2017) and treated orally: 1) 
Low aluminum level - rats were subdivided (N=10/each) and treated for 60 days as follows: a) Untreated – 
received ultrapure water (Milli-Q, Merck Millipore Corporation. © 2012 EMD Millipore, Billerica, MA) 
by drinking water; b) AlCl3 at 8.3 mg/kg bw per day, a dose based on human dietary levels translated to an 
animal dose according to the body surface area normalization method (Reagan-Shaw et al. 2008); and 2) 
High aluminum level - rats were subdivided (N=10/each) and treated for 42 days as follows: a) Untreated 
– received ultrapure water through oral gavage; b) AlCl3 at 100 mg/kg bw per day through oral gavage once 
a day, representing a high level of human exposure to Al (Prakash and Kumar 2009).  
AlCl3.6 H2O was purchased from Sigma-Aldrich (St Louis, MO, USA) and dissolved in ultrapure 
water. The concentration of each stock solution was 0.034 M and 0.331 M, respectively from 8.3 and 100 
mg/kg bw. Salts and reagents were of analytical grade obtained from Sigma-Aldrich and Merck (Darmstadt, 
Germany). 
2.2 Systolic Blood Pressure 
 Indirect systolic blood pressure (SBP) was measured weekly, before the start of the treatment and 
during all the treatment period, using non-invasive tail-cuff plethysmography according to Wiggers et al. 
(2008) (AD Instruments Pty Ltd, Bella Vista, NSW, Australia).  
2.3 Vascular reactivity experiments 
  Rat body weight, feed and water or Al intakes were measured weekly. At the end of the treatments, 
animals were anaesthetized with a combination of ketamine and xylazine (87 mg/kg and 13 mg/kg, 
respectively, ip) and euthanized. Thereafter, the thoracic aorta and the third-order MRA were carefully 
dissected out and cleaned of fat and connective tissues. For vascular reactivity experiments, in the day of 
the euthanasia, the arteries were divided into cylindrical segments of 2 mm in length and placed into Krebs-
Henseleit solution (in mM: NaCl 118; KCl 4.7; NaHCO3 23; CaCl2 2.5; KH2PO4 1.2; MgSO4 1.2; glucose 
11 and EDTA 0.01), gassed with 95% O2 and 5% CO2 (pH 7.4). The remaining aorta and mesenteric 
resistance arteries (MRA) were kept at −80°C for further biochemical/biological assays. 
 Segments of aorta were mounted in an isolated tissue chamber and maintained at a resting tension 
of 1.5 g at 37°C. Isometric tension was recorded using an isometric force transducer (TSD125BX8, Biopac 
Systems, Inc, Santa Barbara, CA, USA) connected to an acquisition system (MP150WSW-SYS, Biopac 
Systems). MRA segments were mounted in a small-vessel dual chamber myograph (Multi Wire Myograph 
System, DMT620, ADInstruments, Australia) for measurement of isometric tension according to Wiggers 
et al. (2008). Segments were stretched to their optimal lumen diameter for active tension development. This 
was determined based on the internal circumference-to-wall tension ratio of the segments by setting their 
internal circumference, Lo, to 90% of what the vessels would have if they were exposed to a passive tension 
equivalent to that produced by a transmural pressure of 100 mmHg.  
 After a 45-min equilibration period, aortic and MRA segments were respectively exposed twice to 
75 and 120 mM KCl, first to check their functional integrity and again to assess the maximal tension 
developed. Afterwards, endothelial integrity was tested with acetylcholine (ACh, 10 μM) in segments that 
were previously contracted with phenylephrine (Phe) at a concentration that produced close to 50% of the 
contraction induced by KCl. After 60 min of washout, a single concentration response curve to Phe (0.01 
nM – 300 μM) was performed.  
 To evaluate the role of the endothelium in the vasoconstrictor responses to Phe, this vascular 
component was mechanically removed, and its absence was confirmed by the inability of ACh to induce 
relaxation greater than 10% of the previous contraction due to Phe. To evaluate the participation of nitric 
oxide (NO), potassium channels, ROS, prostanoids or AT1 receptors on Phe responses, the effects of the 
nonspecific nitric oxide synthase (NOS) inhibitor Nω-nitro-L-arginine methyl ester (L-NAME 100 μM), 
the potassium channels blocker tetraethylammonium (TEA, 2 mM), the NADPH oxidase inhibitor apocynin 
(0.3 μM), the superoxide dismutase (SOD 150 U/ml), the nonselective COX inhibitor indomethacin (1 μM), 
the selective COX-2 inhibitor NS 398 (1 μM) were investigated by their addition 30 min before Phe in 
vessels with intact endothelium. 
 To evaluate the endothelial dependent and independent relaxations, concentration-response curves 
with ACh (0.01 nM – 300 μM) and sodium nitroprusside (SNP, 0.01 nM – 300 μM), respectively, were 
performed in segments previously contracted with Phe. 
2.4 Aluminum content in blood and liver 
 The Al content of blood and liver was determined using an established method (House et al. 2012). 
Briefly, approximately 0.5g of liver was dried to a constant weight at 37ºC. Dried and weighed tissues and 
1 mL of blood, were digested in a 1:1 mixture of 15.8M HNO3 and 30% w/v H2O2 in a microwave oven 
(MARS Xpress CEM Microwave Technology Ltd) and the Al content of digests measured by TH GFAAS 
(Transversley Heated Graphite Furnace Atomic Absorption Spectrometry). Results were expressed as μg 
Al/L of blood or μg Al/g dry tissue. Each determination was the arithmetic mean of a triplicate analysis. 
2.5 Reactive oxygen species levels 
 Biochemical studies of oxidative stress biomarkers were performed in aorta and MRA. For that, 
vessels were homogenized in 50 mM Tris HCl, pH 7.4, centrifuged at 2400g for 10 min at 4C and the 
resulting supernatant fraction was used for the measurements. 
Levels of reactive species were determined by the spectrofluorometric method described by 
Loetchutinat et al. (2005). This method is unspecific for reactive oxygen species (ROS), also measuring 
reactive nitrogen species (RNS). The supernatant fraction of the sample was diluted (1:10) in 50 mM Tris 
HCl (pH 7.4) and 2′, 7′-dichlorofluorescein diacetate (DCHF-DA; 1mM) was added to the medium. DCHF-
DA is enzymatically hydrolyzed by intracellular esterases to form nonfluorescent DCFH, which is then 
rapidly oxidized to form highly fluorescent 2´,7´-dichlorofluorescein (DCF) in the presence of ROS. DCF 
fluorescence intensity is proportional to the amount of ROS that is formed. The DCF fluorescence intensity 
emission was recorded at 520 nm (with 480 nm excitation) (SpectraMax M5 Molecular Devices, CA, USA) 
for 60 min at 15 min intervals. The ROS levels were expressed as fluorescence units. 
2.6 Lipid peroxidation 
Lipid peroxidation was measured as malondialdehyde (MDA) using a colorimetric method, as 
previously described by Ohkawa et al. (1979), with modifications (Martinez et al. 2017). An aliquot of each 
tissue was incubated with thiobarbituric acid 0.8% (TBA), phosphoric acid buffer 1% (H3PO4), and sodium 
dodecyl sulphate 0.8% (SDS) at 100ºC for 60 min. The color reaction was measured at 532 nm against 
blanks (SpectraMax M5 Molecular Devices, CA, USA). The results were expressed as nanomoles of MDA 
per mg of protein.  
2.7 Ferric Reducing/Antioxidant Power (FRAP) Assay 
The total antioxidant capacity was measured by FRAP assay (Benzie and Strain 1996), with 
modifications (Martinez et al. 2017). This method is based on the ability of samples to reduce ferric ion 
(Fe3+) to ferrous ion (Fe2+) which forms with 2,4,6-Tri(2-piridil)-s- triazine (TPTZ) the chelate complex 
Fe+2-TPTZ. Briefly, 10 𝜇L of the supernatant fraction of each tissue was added to 1 mL freshly prepared 
and pre-warmed (37∘C) FRAP reagent (300mM acetate buffer (pH = 3.6), 10mM TPTZ in 40mM HCl, and 
20mM FeCl3 in the ratio of 10:1:1) in a test tube and incubated at 37∘C for 10min. The absorbance of the 
blue-colored complex was read against a blank reagent (1 mL FRAP reagent + 10 𝜇L distilled water) at 593 
nm (SpectraMax M5 Molecular Devices, CA, USA). A standard dose-response curve of Trolox (50-1000 
μM – water soluble analog of vitamin E) was prepared and the FRAP assay is described. Results are 
presented with particular reference to Trolox equivalents. 
2.8 In situ detection of vascular O2•- production  
The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate in situ superoxide 
radical anion (O2•-) production in both aortic and mesenteric segments, as previously described (Briones et 
al. 2009). Hydroethidine freely permeates cells and is oxidized in the presence of O2•- to ethidium bromide, 
which is trapped by intercalation with DNA. Ethidium bromide is excited at 546 nm and has an emission 
spectrum at 600–700 nm. Frozen tissue segments were cut into 10 μm thick sections and placed on a glass 
slide. Serial sections were equilibrated under identical conditions for 30 min at 37°C in Krebs-HEPES 
buffer (in mM/L: 130 NaCl, 5.6 KCl, 2 CaCl2, 0.24 MgCl2, 8.3 HEPES, 11 glucose, pH=7.4). Fresh buffer 
containing DHE (2x10-6 M/L) was applied topically into each tissue section, cover-slipped, incubated for 
30 min in a light protected humidified chamber at 37°C and then viewed with a fluorescent microscope 
(Zeiss Axioskop 2 microscope - Zeiss, Jena, Germany- Leica TCS SP2 equipped with a krypton/argon laser, 
x20 objective, zoom 4x), using the same imaging settings in control and arteries from Al-treated rats. 
Fluorescence was detected with a 568 nm long-pass filter. For quantification, five rings per animal were 
sampled for each experimental condition and averaged. The mean fluorescence densities in the target region 
were calculated using NIH Image J software version 1.46r (http://rsbweb.nih.gov/ij/), using the same 
imaging settings in each case.  
2.9 Lucigenin Chemiluminescence Assay  
A lucigenin-enhanced chemiluminescence assay was used to determine NAD(P)H (NOX) activity. 
Aortas were homogenized in lysis buffer (50 mM KH2PO4, 1 mM EGTA, and 150 mM sucrose, pH 7.4). 
The reaction was started by the addition of NADPH (0.1 mM) to the suspension containing the sample, 
lucigenin (5 μM), and assay phosphate buffer. Luminescence was measured in a plate luminometer (Auto-
Lumat LB 953, Berthold Technologies, Bad Wildbad, Germany). The buffer blank was subtracted from 
each reading. Activity was expressed as relative light units per microgram of protein.  
2.10 Quantitative real time PCR assay 
 The mRNA expression levels were determined by quantitative real-time PCR. Total RNA was 
obtained using TRIzol (Invitrogen Life Technologies). A total of 1 μg of DNAse I-treated RNA was reverse 
transcribed into cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA) 
in a 10-μl reaction. qRT-PCR was performed in duplicate for each sample using 0.5 μl cDNA as template, 
1X iTaq™ Universal Probes Supermix (Biorad), and 20X Taqman Gene Expression Assays (COX-2: 
Rn00568225_m1, NOX-1: Rn00586652_m1, SOD-1: Rn00566938_m1, TXA2 receptor: Rn00690601_m1, 
Applied Biosystems) in a 10-μl reaction using the following conditions: 2 min at 50°C and 10 min at 95°C 
and 40 cycles of 15s at 95°C and 1 min at 60°C. qRT-PCR for eNOS (Fd: 
GAGAGTGAGCTGGTGTTTGG; Rv: GGTGAACATTTCCTGTGCTGT)  and NOX-2 (Fd: 
CCAGTGTGTCGGAATCTCCT; Rv: ATGTGCAATGGTGTGAATGG), were performed using the 
fluorescent dye SyBRGreen (iTaq FAST SyBRGreen Supermix with ROX, Bio-Rad, USA). For 
quantification, quantitative real-time PCR was carried out in a 7500 Fast (Applied Biosystems) adding a 
dissociation stage to the conditions already described above to show PCR product speciﬁcity. As a 
normalizing internal control, we amplified cyclophilin D (Rn01458749_g1). To calculate the relative index 
of gene expression, we employed the 2−ΔΔCt method using untreated samples as a calibrator (Livak and 
Schmittgen 2001). mRNA levels of the housekeeping gene were not modified by any of the treatments 
used.  
2.11 Statistical analysis 
Data are expressed as mean ± SEM. In the vascular reactivity experiments, vasoconstrictor responses 
of aorta and MRA were expressed as a percentage of the contraction induced by 75 mM and 120 mM KCl, 
respectively.Vasodilator responses were expressed as a percentage of the previous contraction to Phe. To 
compare the effect of L-NAME, TEA, apocynin, SOD, indomethacin and NS-398 -on the response to Phe 
in segments from each group, some results were expressed as ‘differences of area under the concentration-
response curves’ (dAUC) in control and experimental situations AUCs were calculated from the individual 
concentration response curve plots; differences were expressed as the percentage of the AUC of the 
corresponding control situation. Results were analyzed using unpaired Student’s t-test or two-way ANOVA 
for comparison between groups. When ANOVA showed a significant treatment effect, Bonferroni's post 
hoc test was used to compare individual means. Results of biochemical experiments were analyzed using 
Student’s t-test or Mann-Whitney test. Values of P < 0.05 were considered significant. 
3. Results  
3.1 Body weight, fluid and feed intake and aluminum content  
Body weight of rats was similar between groups at the beginning and end of treatments. Water or 
Al intakes as well as the feed intake were not different between groups (Martinez et al. 2017). The whole 
blood Al content was similar in rats treated with the low dose of Al (Untreated: 73.43 ± 1.7 vs Al 8.3: 77.1 
± 6.6 μg Al/L/blood, P > 0.05) while that of the rats treated with the high dose was greater that the 
corresponding control (Untreated: 78.9 ± 5.7 vs Al 100: 121.1 ± 11.2 μg Al/L/blood, P < 0.05). However, 
liver Al contents were greater both in the low (Untreated: 0.25 ± 0.01 vs Al 8.3: 0.44 ± 0.04 μg Al/g/dry 
tissue, P < 0.05) and also in the high Al-treated groups (Untreated: 0.26 ± 0.01 vs Al 100: 0.72 ± 0.01 μg 
Al/g/dry tissue, P < 0.05).  
3.2 Aluminum raises systolic blood pressure 
Exposure to Al at low (8.3 mg/kg bw for 60 days) or at high level (100 mg/kg bw for 42 days) 
increased SBP after the 3rd week of treatment (Untreated: 119.0 ± 1.4 vs Al 8.3: 129.2 ± 1.0 mmHg, n=8, P 
< 0.05; Untreated: 120.5 ± 1.5 vs Al 100: 131.5 ± 3.7 mmHg, n=8, P < 0.05). However, at the end of 
treatments only Al at the higher dose maintained this increase (Fig 1A, B).  
3.3 Aluminum increases vascular reactivity and induces vascular dysfunction  
Al exposure did not affect the response to KCl either in aorta (Untreated: 3.8 ± 0.3 vs Al 8.3: 4.1 ± 
0.4 mN/mm;  Untreated: 3.9 ± 0.2 vs Al 100: 4.1 ± 0.3 mN/mm; n= 15 to 20 , P > 0.05) or MRA (Untreated: 
3.6 ± 0.2 vs Al 8.3: 3.5 ± 0.3 mN/mm; Untreated: 4.1 ± 0.3 vs Al 100: 4.5 ± 0.2 mN/mm, n = 15 to 20, P > 
0.05). However, Al treatment at both low and high levels increased the vasoconstrictor responses to Phe in 
aorta and MRA while decreased the endothelium-dependent responses induced by ACh only in MRA (Figs 
2A, B, Table 1). The vasodilator response induced by SNP were unaffected by Al exposure (data not 
shown). These results suggest that Al affects vasoconstrictor responses in both conductance and resistance 
arteries and impairs endothelial function only in resistance arteries. 
3.4 Aluminum decreases the endothelial modulation of the vasoconstrictor response – Involvement of 
endothelial NO synthase  
To investigate whether Al exposure alters NO modulation on vasoconstrictor responses, the effect 
of endothelium removal and incubation with the NOS inhibitor L-NAME (100 μM), were investigated. 
Both endothelium removal and NOS inhibitor addition left-shifted the concentration–response curves to 
Phe in aorta and MRA segments from the four groups, but this effect was smaller in preparations from rats 
treated with either 8.3 mg/Kg or 100 mg/Kg of Al than in those from untreated rats, as shown by the dAUC 
values (Figs 3, 4). The endothelial modulation was impaired after Al exposure at an equivalent human 
dietary level and this effect was almost the same as observed after Al treatment at 12 times higher. 
Therefore, we decided to investigate the underling mechanisms of Al toxicity by using the human relevant 
dose level and, Al exposure at 8.3 mg/kg decreased eNOS gene expression in aorta (Untreated: 0.85 ± 0.1 
vs Al 8.3: 0.60 ± 0.1 relative expression, P < 0.05). To verify the influence of K+ channels on the 
vasoconstrictor responses, aortic segments were incubated with TEA (2 mM), a K+ channel blocker. The 
presence of TEA increased the contractile response to Phe in all groups, but this enhancement was smaller 
in aorta from Al-treated rats, as demonstrated by the dAUC values (Fig 5). All these findings suggest that 
the production and/or bioavailability of NO are impaired by Al exposure at both high and low level. The 
reduced participation of K+ channels on vasoconstrictor responses follow the results of lower NO 
bioavailability, since NO can direct (Bolotina et al. 1994; Mistry & Garland 1998) or indirectly by cyclic 
GMP-dependent (Carrier et al. 1997) promote the activation of K+ channel in MRA.   
3.5 Aluminum increases oxidative stress – Role of NAD(P)H oxidase 
The participation of oxidative stress in the vascular responses was evaluated in vitro using the non 
selective NAD(P)H oxidase inhibitor apocynin as well as  SOD. Apocynin (0.3 μM) and SOD (150 U/ml) 
reduced the vascular response to Phe in MRA from rats treated with both doses of Al, while those drugs 
did not affect the response in untreated animals (Fig 6); in aorta, both apocynin and SOD reduced the Phe-
induced responses, being this effect greater in segments from Al-treated rats than from untreated rats, as 
demonstrated by the dAUC values (Fig 7). Al exposure either at low doses or at high doses increased 
vascular ROS and lipid peroxidation levels (ROS (UF): Aorta - Untreated: 98.4 ± 15.3 vs Al 8.3: 152.9 ± 
9.7; Untreated: 98.4 ± 15.3 vs Al 100: 201.2 ± 24.1; MRA - Untreated: 129.2 ± 12.3 vs Al 8.3: 231.7 ± 22.7, 
Untreated: 157.3 ± 13.2 vs Al 100: 228.5 ± 15.6 - n=8, P < 0.05; Lipid peroxidation (nM MDA/mg protein): 
Aorta - Untreated: 37.1 ± 2.1 vs Al 8.3: 50.3 ± 4.1; Untreated: 18.3 ± 0.6 vs Al 100: 30.6 ± 5.4; MRA -  
Untreated: 8.3 ± 1.3 vs Al 8.3: 15.7 ± 2.7; Untreated: 7.2 ± 1.0 vs Al 100: 20.3 ± 2.3 - n=8, P < 0.05). Al at 
both doses increased the MRA total antioxidant capacity (FRAP value (mM): Untreated: 32.1 ± 3.5 vs Al 
8.3: 78.8 ± 4.3; Untreated: 35.9 ± 4.1 vs Al 100: 53.5 ± 5.9 - n= 8, P < 0.05), while in aorta the antioxidant 
capacity was reduced after Al exposure at 8.3 mg/kg (FRAP value (mM): Untreated: 64.1 ± 9.1 vs Al 8.3: 
26.6 ± 4.0 P < 0.05, Untreated: 45.2 ± 2.5 vs Al 100: 42.9 ± 2.9 - n= 8, P > 0.05). Taking all together, these 
results suggest that the reduced NO bioavailability could be related with the increased oxidative stress after 
Al exposure.   
NAD(P)H oxidase complex plays an important role on O2•- production (Martyn et al. 2006). 
Therefore, we investigated its possible role as source of ROS production after Al exposure. The basal O2•− 
production increased in both conductance and resistance arteries from rats treated with 8.3 mg/Kg (Fig 8). 
The NAD(P)H oxidase activity and the NOX1 gene expression were both increased in aorta from the Al-
treated group compared to untreated group (Fig 9A,B); however, NOX2 mRNA was similar in treated and 
untreated animals (Fig 9C). Moreover, Al treatment inhibited the SOD1 gene expression in aorta from Al-
treated animals (Fig 9D).  
3.6 Aluminum vascular impairment - Participation of COX-2-derived prostanoids  
To investigate the role of prostanoids on the increased response to Phe in Al-treated rats, the 
cyclooxygenase inhibitor indomethacin and the selective COX-2 inhibitor NS 398 were used. Indomethacin 
(1 μM) and NS 398 (1 μM) reduced the vasoconstrictor response to Phe in both arteries from all groups. 
However, as observed by the dAUC values, this reduction was greater in segments from both Al-treated 
groups when compared to the untreated groups (Fig 10, 11), suggesting an increased participation of 
contractile prostanoids from COX-2 on Phe-induced responses. Al exposure at the human relevant level of 
8.3 mg/kg increased the mRNA levels of both COX-2 and TXA-2 R in aorta (Fig 12). These results suggest 
that COX-2-derived prostanoids, probably acting on TP receptors, play a role on the vascular impairment 
observed after Al exposure at human dietary relevant level.  
4. Discussion  
The present study provides evidence that Al should be considered as a risk to the cardiovascular 
system even at low doses. Here, we show that Al exposure for 60 days at human dietary levels increased 
blood pressure and vascular reactivity in both conductance and resistance vessels through endothelium-
dependent mechanisms. Moreover, these effects were almost the same when we treated rats with Al at a 
dose 12 times higher (100 mg/kg), representing a high level of human exposure to Al. We demonstrate that 
ROS and COX-2-derived prostanoids are important mediators of aorta and mesenteric vascular dysfunction 
observed after Al exposure. The excess of ROS mainly from NAD(P)H oxidase and the increased vascular 
COX-2 act in concert to decrease NO bioavailability, thus inducing vascular dysfunction and increased 
blood pressure.  
Due to the omnipresence of Al in our daily life, human exposure to Al is still underestimated (Exley 
2013). The tolerable weekly intake of Al for humans has been set at 1 mg Al/Kg bw (EFSA 2008; WHO 
2007), which may be easily exceed by humans due to myriad sources of Al exposure (Exley 2013; Fekete 
et al. 2013; Gonzalez-Weller et al. 2010; Yang et al. 2014). We have recently established an experimental 
model of exposure to Al that mimics human exposure to this metal through diet in which rats were exposed 
to Al at a dose of 8.3 mg/Kg bw per day during 60 days. Considering the amount of Al present in the 
animal´s feed, the total Al exposure was 4.37 mg/Al/day (2.49 mg from water plus 1.88 mg from feed). In 
addition, we have compared this low dose with a high level of human exposure to Al (100 mg/Kg bw), in 
which rats were treated with a total of 31.88 mg/Al/day (30 mg from gavage plus 1.88 mg from feed) 
(Martinez et al. 2017). In the present study, Al exposure at low dose did not change the whole blood Al 
content between groups; however it promoted an increased Al accumulation in the liver. The lack of 
differences for blood contents after Al exposure at a low dose is expected since blood is only a temporal 
storage organ for Al (Beardmore and Exley 2009). The high deposition of Al in the liver even without 
differences in the blood level supports these findings. Of interest, the human blood Al content is extremely 
variable in the available literature, ranging from less than 1 to 901 μg Al/L of blood (Chen et al. 2013; Lind 
et al. 2012)  
Cardiovascular risk and human body burden of Al share the characteristic that both rise with increase 
of average lifetime (Assmann et al. 2017; Exley 2013). Therefore, considering the postulated mechanisms 
of action of Al and the underling ones regarding vascular disease, for example increased oxidative stress, 
finding more relations between them would not be a surprise. In previous years, studies have analyzed the 
possible cardiovascular adverse effects of Al exposure. Isolated rat hearts exposure to Al at 100 μM showed 
a reduction of both coronary blood flow and isovolumetric systolic pressure (Gomes et al. 1994). The effects 
of Al on heart function was further analyzed and the perfusion of hearts with Al at 40 μM caused an increase 
in coronary flow and both reduction in heart rate and increases in pulsatile power (Korchazhkina et al. 
1998).  
More recently, Al was related to the development of hypertension in experimental animals, these 
effects were related to an increase in renin expression or erythrocyte membrane impairments after acute or 
chronic Al administration up to 256 mg/kg (Ezomo et al. 2009; Zhang et al. 2015). In humans, this possible 
relationship was also seen, where circulating plasma Al levels were related to arterial hypertension 
(Granadillo et al. 1995). In a recent study, our group showed that one hour of Al exposure at 100 mg/kg is 
sufficient to promote vascular changes with reduction in vascular reactivity and increase in vascular ROS 
production (Schmidt et al. 2016). To our knowledge, our study is the first experimental one investigating 
and showing cardiovascular effects after Al exposure at human relevant dietary levels. The current study 
supports the possible cardiovascular risk of Al. Thus, the main results show that Al exposure: 1) increases 
systolic blood pressure; 2) produced endothelial dysfunction, as shown by the impaired the vasodilator 
response to ACh and the increased vasoconstrictor responses to Phe and 3) reduced the endothelial NO 
bioavailability.  
Al3+ toxicity has been related with its pro-oxidant activity in different target organs and systems in 
experimental animals (Prakash and Kumar 2009; Yu et al. 2016). The pro-oxidant effects of Al are well 
documented and are possible due to formation of superoxide radical ion (Exley 2004) or by promoting the 
Fenton reaction by reducing Fe(III) to Fe(II) (Ruipérez et al. 2012). It is well known that oxidative stress 
alters vascular reactivity through several ways such as its effects on the NO pathway, by counteracting NO 
effects or by reducing its bioavailability (Hernanz et al. 2014). NO can rapidly react with O2•-, promoting 
the formation of the powerful oxidant ONOO−, leading to the loss of the vasodilator effects of NO (Alvarez 
et al. 2008; Zou 2007). In the present study, the suggested reduced NO bioavailability could be due to the 
inhibited eNOS gene expression or due to a direct effect of the increased oxidative stress.  
NADPH oxidases play a central role in the production of vascular superoxide radical anion and 
hydrogen peroxidase (Konior et al. 2014). The isoforms NOX-1 and NOX-2 expressed in mammals seem 
to trigger the development of vascular pathologies such as atherosclerosis, hypertension, neurological 
disorders, inflammation and cancer (Konior et al. 2014; Schramm et al. 2012). In our study, the in vitro 
exposure to apocynin and to the antioxidant SOD promoted a higher reduction in the vasoconstrictor 
response to Phe in segments from Al-treated rats, suggesting the involvement of the superoxide radical 
anion, presumably from NADPH oxidase, on vascular dysfunction induced by Al. This was further support 
by the fact that the basal O2•- production, the mRNA levels of NOX-1 subunit and the NADPH oxidase 
activity were increased while the mRNA levels of cytosolic Cu/Zn SOD was decreased in Al-treated rats. 
Moreover, the vascular redox imbalance suggested by the increased ROS and lipid peroxidation as well as 
by the antioxidant capacity alterations, support that Al induced pro-oxidant mechanisms likely explained 
the observed vascular alterations. 
Vascular tone is critically modulated by COX-derived prostanoids and its vascular effects in 
physiological and pathological conditions are depending on the activation of specific receptors (Hernanz et 
al. 2014; Avendaño et al. 2016). Recently, a circuitous relationship between COX-2 products and ROS 
acting to induce vascular dysfunction in hypertension was shown (Martinez-Revelles et al. 2013). The 
toxicity effects of Al have been strongly related with its pro-oxidant capacity (Exley 2004; Ruipérez et al. 
2012; Yu et al. 2016) and, recently an involvement of COX-2 pathway in the neuro-pathological effect of 
Al has been suggested (Yu et al. 2014; Wang et al. 2015). In the present study we found that the respective 
unspecific and specific inhibitors of COX-2, indomethacin and NS 398, promoted a reduction in the 
vasoconstrictor response to Phe mainly in aortic and MRA segments of Al-treated rats. These results 
suggests the participation of COX-2 derived prostanoids in the vascular dysfunction observed after Al 
exposure. In agreement, aortas from Al-treated rats showed an increase on mRNA levels of COX-2 and 
TXA-2 R. The TXA-2 R is involved in critical regulations of the vascular wall such as platelet aggregation 
and smooth muscle contraction and vascular changes of hypertension (Félétou et al. 2011; Nakahata 2008). 
Here, its activation seems to play a role in vascular alterations found in Al-treated rats, however further 
experiments are necessary to better address this hypothesis. 
5. Conclusions 
Our study provides evidence that 60-day exposures to low doses of Al, which aimed to mimic human 
exposure to Al by dietary source, are able to compromise cardiovascular health. The current study shows 
that Al increases systolic blood pressure and vascular reactivity through endothelium-dependent 
mechanisms. Here, we demonstrate that ROS and COX-2-derived prostanoids are important mediators of 
vascular dysfunction after Al exposure. The excess of ROS mainly from NAD(P)H oxidase and  increased 
vascular COX-2 seem to participate in the vascular alterations after Al exposure. Both act in concert to 
decrease NO bioavailability, which in turn induces vascular dysfunction and increases blood pressure. 
Therefore, our findings provide a better understanding of the cardiovascular risk of human exposure to Al. 
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Figure legends 
 
Figure 1. Effect of chronic aluminum exposure on non-invasive systolic blood pressure. Values of systolic 
blood pressure (mmHg) of untreated rats and treated with AlCl3 for 60 (8.3 mg/kg bw per day - A) or 42 
days (100 mg/kg bw per day - B). Data are expressed as mean ± SEM, n=8, * P < 0.05 compared with their 
corresponding controls (untreated rats) (Two-Way ANOVA followed by Bonferroni).  
 
Figure 2. Effect of chronic aluminum exposure on vascular reactivity. Concentration–response curves to 
(A) phenylephrine and (B) acetylcholine in aorta and MRA segments. Data are expressed as mean ± SEM, 
n=8 to 15, * P < 0.05 compared with their corresponding Untreated groups (Two-Way ANOVA followed 
by Bonferroni).  
 
Figure 3. Effect of chronic aluminum exposure on NO-mediated vascular response in MRA. Effects of (A) 
endothelium removal (E−) and (B) L-NAME (100 μM) on the concentration-response curve to 
phenylephrine from untreated and Al-treated rats. The inset shows differences in the area under the 
concentration–response curves (dAUC) in (A) endothelium-denuded and intact segments and (B) in the 
presence and absence of L-NAME. Data are expressed as mean ± SEM, n=8 to 15, * P < 0.05 vs control 
curve (Two-Way ANOVA followed by Bonferroni) * P < 0.05 vs Untreated (Student’s t-test) in dAUC 
graphs. 
 
Figure 4. Effect of chronic aluminum exposure on NO-mediated vascular response in aorta. Effects of (A) 
endothelium removal (E−) and (B) L-NAME (100 μM) on the concentration-response curve to 
phenylephrine in aorta from untreated and Al-treated rats. The inset shows differences in the area under the 
concentration–response curves (dAUC) in (A) endothelium-denuded and intact segments and (B) in the 
presence and absence of L-NAME. Data are expressed as mean ± SEM, n=8 to 15, * P < 0.05 vs control 
curve (Two-Way ANOVA followed by Bonferroni) * P < 0.05 vs Untreated (Student’s t-test) in dAUC 
graphs. 
 
Figure 5. Effect of chronic aluminum exposure on K+ channels action on the vascular response in aorta. 
Effects of (A) the K+ channels blocker TEA (2 mM) on the concentration-response curve to phenylephrine 
in aorta from untreated and Al-treated rats. The inset shows differences in the area under the concentration–
response curves (dAUC) in (A) in the presence and absence of TEA. Data are expressed as mean ± SEM, 
n=8 to 15, * P < 0.05 vs control curve (Two-Way ANOVA followed by Bonferroni) * P < 0.05 vs Untreated 
(Student’s t-test) in dAUC graphs. 
 
Figure 6. Effect of chronic aluminum exposure on ROS-mediated vascular response in MRA. Effects of 
(A) NOX oxidase inhibitor apocynin (0.3 μM) and (B) SOD (150 U/ml) on the concentration-response 
curve to phenylephrine in MRA from untreated and Al-treated rats. The inset shows differences in the area 
under the concentration–response curves (dAUC) in (A) in the presence and absence of apocynin and (B) 
in the presence and absence of SOD. Data are expressed as mean ± SEM, n=8 to 15, * P < 0.05 vs control 
curve (Two-Way ANOVA followed by Bonferroni) * P < 0.05 vs Untreated (Student’s t-test) in dAUC 
graphs. 
 
Figure 7. Effect of chronic aluminum exposure on ROS-mediated vascular response in aorta. Effects of 
(A) NOX oxidase inhibitor apocynin (0.3 μM) and (B) SOD (150 U/ml) on the concentration-response 
curve to phenylephrine in aorta from untreated and Al-treated rats. The inset shows differences in the area 
under the concentration–response curves (dAUC) in (A) in the presence and absence of apocynin and (B) 
in the presence and absence of SOD. Data are expressed as mean ± SEM, n=8 to 15, * P < 0.05 vs control 
curve (Two-Way ANOVA followed by Bonferroni) * P < 0.05 vs Untreated (Student’s t-test) in dAUC 
graphs. 
 
Figure 8. Effect of chronic aluminum exposure on vascular O2- production. Representative fluorescent 
photomicrographs of arterial sections labeled with the oxidative dye hydroethidine and vascular superoxide 
anion quantification in MRA (A) and aorta (B) from untreated and Al-treated rats (8.3 mg/kg – 60 days). 
Data are expressed as mean ± SEM (n = 8). * P < 0.05 compared with the untreated group (Student’s t-
test). Au: Fluorescence intensity. 
 
Figure 9. Effect of chronic aluminum exposure on NOX oxidase enzyme activity, NOX-1, NOX-2 and 
SOD 1 gene expressions. NOX oxidase activity (A) and mRNA levels for NOX-1 (B), NOX-2 (C) and 
SOD 1 (D) in aortas from untreated and Al-treated rats (8.3 mg/kg – 60 days). Data are expressed as mean 
± SEM (n = 8). * P < 0.05 compared with the untreated group (Student’s t-test). 
 
Figure 10. Effect of chronic aluminum exposure on COX-derived prostanoids role on vascular response in 
MRA. Effects of (A) cyclooxygenase inhibitor indomethacin (1 μM) and (B) selective COX-2 inhibitor NS 
398 (1 μM) on the concentration– response curve to phenylephrine in MRA from untreated and Al-treated 
rats. The inset shows differences in the area under the concentration–response curves (dAUC) in (A) in the 
presence and absence of indomethacin and (B) in the presence and absence of NS 398. Data are expressed 
as mean ± SEM, n=8 to 15, * P < 0.05 vs control curve (Two-Way ANOVA followed by Bonferroni) * P 
< 0.05 vs Untreated (Student’s t-test) in dAUC graphs. 
 
Figure 11. Effect of chronic aluminum exposure on COX-derived prostanoids role on vascular response in 
aorta. Effects of (A) cyclooxygenase inhibitor indomethacin (1 μM) and (B) selective COX-2 inhibitor NS 
398 (1 μM) on the concentration– response curve to phenylephrine in aorta from untreated and Al-treated 
rats. The inset shows differences in the area under the concentration–response curves (dAUC) in (A) in the 
presence and absence of indomethacin and (B) in the presence and absence of NS 398. Data are expressed 
as mean ± SEM, n=8 to 15, * P < 0.05 vs control curve (Two-Way ANOVA followed by Bonferroni) * P 
< 0.05 vs Untreated (Student’s t-test) in dAUC graphs. 
 
Figure 12. Effect of chronic aluminum exposure on COX-2 and TXA-2 R gene expressions. COX-2 mRNA 
levels (A) and TXA-2 R mRNA levels (B) in aortas from untreated and Al-treated rats (8.3 mg/kg – 60 
days). Data are expressed as mean ± SEM (n = 8). * P < 0.05 compared with the untreated group (Student’s 
t-test).  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Table 1 Effects of aluminum exposure to low and high doses on maximum response (Rmax) and sensitivity 
(pD2) 
 Untreated Al 8.3 mg/kg                       Untreated Al 100 mg/kg 
 Rmax pD2 Rmax pD2 Rmax               pD2 Rmax                 pD2 
Aorta       
Control 89.7 ± 4.3 6.3 ± 0.1 111.1 ± 5.1# 6.5 ± 0.1 86.7 ± 6.5          6.3 ± 0.1        107.2 ± 7.4#               6.4 ± 0.1 
E- 110.6 ± 6.2* 6.7 ± 0.1* 109.1 ± 2.4 7.1 ± 0.1* 116.6 ± 5.5*        7.1 ± 0.1*     108.5 ± 6.1          7.1 ± 0.2* 
L-NAME 129.5 ± 5.1* 6.9 ± 0.1* 126 ± 5.5 7.2 ± 0.1* 127.3 ± 4.6*        7.1 ± 0.2*     129.2 ± 5.5*        7.1 ± 0.1* 
TEA 126.9 ± 4.2* 7.0 ± 0.0* 123.5 ± 5.1 7.1 ± 0.1* 118.1 ± 5.8*         7.2 ± 0.3*     112.1 ± 7.1         7.0 ± 0.2* 
Apocynin 44.6 ± 5.4* 6.3 ± 0.1 46.6 ± 4.2* 6.4 ± 0.1 50.3 ± 6.3*         6.2 ± 0.1     41.3 ± 4.0*         5.9 ± 0.1* 
SOD 89.2 ± 11.2  6.0 ± 0.1 89.7 ± 8.3* 5.8 ± 0.1* 74.9 ± 13.3         6.0 ± 0.1     81.6 ± 9.8          5.7 ± 0.1* 
 Parameters of maximal response (Rmax) and sensitivity (pD2) of the concentration-response curves to phenylephrine in both aorta and 
MRA before (control) and after endothelial damage (E-), L-NAME (100 μM), TEA (2 mM), apocynin (0.3 μM), SOD (150 U/ml), 
Indomethacin (1μM) and NS 398 (1μM) incubations. Results are expressed as mean ± SEM. Rmax: maximal effect (expressed as a 
percentage of maximal response induced by KCl) and pD2 expressed as a -log one-half Rmax.* P < 0.05 compared to the corresponding 
control in each group # P < 0.05 compared with the Untreated group (Student’s t-test). 
 
Indomethacin 55.1 ± 3.3* 6.4 ± 0.1 62.9 ± 6.6* 6.5 ± 0.1 56.9 ± 7.3*         6.1 ± 0.1    54.3 ± 6.4*        6.2 ± 0.18 
NS 398 51.3 ± 5.9* 6.1 ± 0.1 55.1 ± 4.6* 6.3 ± 0.1 58.2 ± 8.3*         6.3 ± 0.1    50.8 ± 6.5*        6.1 ± 0.1* 
MRA       
Control 111 ± 1.8 4.2 ± 0.2 123 ± 3.4# 5.1 ± 0.2# 109.1 ± 3.1          3.7 ± 0.2 120 ± 2.7#              4.7 ± 0.3# 
E- 120 ± 3* 5.1 ± 0.4 117.1 ± 2.8 4.1 ± 0.3 123.3 ± 4.5*        5.4 ± 0.4* 114.4 ± 2.8       4.3 ± 0.3 
L-NAME 130.4 ± 4.7* 5.3 ± 0.4* 126.9 ± 5.1 5.1 ± 0.4 135.2 ± 6.2*        5.1 ± 0.6 122.4 ± 3.6       5.1 ± 0.3  
Apocynin 116.2 ± 3.9 3.9 ± 0.3 114.3 ± 3.4* 4.3 ± 0.1* 119.5 ± 4.2           4.9 ± 0.2* 115.5 ± 3.2         4.4 ± 0.3 
SOD 129.1 ± 3.5* 5.2 ± 0.3* 125 ± 4.6 4.9 ± 0.5 
 
135 ± 5.8            5.3 ± 0.1* 123.5 ± 3.6         4.8 ± 0.2 
Indomethacin 103.3 ± 3.1* 3.1 ± 0.3* 105.3 ± 3.1* 2.9 ± 0.3* 111.1 ± 7.6          4.1 ± 0.5 114.8 ± 5.2         4.1 ± 0.3  
NS 398 125.2 ± 2.7* 4.7 ± 0.2 118.4 ± 3.3* 4.4 ± 0.2 129.7 ± 0.3*         4.7 ± 0.3 128.8 ± 2.4         5.2 ± 0.7 
